



supplementary


Effect of Cholesterol on the Organic Cation Transporter OCTN1 (SLC22A4)

Lorena Pochini, Gilda Pappacoda, Michele Galluccio, Francesco Pastore, Mariafrancesca Scalise,
and Cesare Indiveri*

Department of Biology, Ecology and Earth Sciences (DiBEST), Unit of Biochemistry and Molecular
Biotechnology, University of Calabria, via P. Bucci 4c, 87036 Arcavacata di Rende, Italy;
lorena.pochini@unical.it (L.P.); gilda.pappacoda@gmail.com (G.P.); michele.galluccio@unical.it (M.G.);
francesco.pastore92@gmail.com (F.P.); mariafrancesca.scalise@unical.it (M.S.); cesare.indiveri@unical.it (C.I.).

* Correspondence: cesare.indiveri@unical.it; Tel.: +39-0984-492939

11



12 **Supplementary Figure 1. Effect of CHS on the inhibitory effect by HgCl₂ on the hOCTN1.** The
 13 recombinant hOCTN1 was reconstituted in liposomes as described in section 4.5. except that in the
 14 absence (○) or in the presence (●) of 8.3 % CHS corresponding to 83 µg CHS/mg total lipids. Transport
 15 was started adding 0.1 mM [¹⁴C]-TEA at time zero to proteoliposomes in the presence of increasing
 16 HgCl₂ concentrations (0-0.05-0.1-0.25-0.5-1 mM). The transport reaction was stopped at 20 minutes.
 17 Percent residual activity with respect to the control data were interpolated by an IC₅₀ equation (Dose-
 18 response curves). The values are means ± SD from three experiments.

19

```

OCTN1  -MRDYDEVIAFLGEWGPFRLLIFFLLSASIIPNGFNGMSVVFAGTPEHRCRVPDAANLSS--AWR-----NNSVPLRLR
OCT2    MPTTVDDVLEHGGEFHFFQKQMFLLALLSATFAPIYVGIVFLGFTPDHRCRSPGVAELSLRCGWSPAEELNYTPGPGP

OCTN1  DGREVPHSCSRYRLAT- IANFSALGLEPGRDVLGQLEQESCLDGWEFSQDVYLSTVVTEWNLVCEDNWKVPLTTSLFFV
OCT2    AGEASPRQCRRYEVDWQSTFDCVDPLASLDTNRSRLPLGPCRDGWVYETPG--SSIVTEFNLCANSWMLDLFQSSNV

OCTN1  GVLLGSFVSGQLSDRFRGNVLFATMAVQTGFSLQIFSISWEMFTVLFVIVGMGQISNYVVAFILGTEILGKSVRIIFS
OCT2    GFFIGSMSIGYIADRFGRKLCLLTVLINAAAGVLMASPTYTWMLIFRLIQGLVSKAGWLGILGYILITEFVGRYRRTVG

OCTN1  TLGVCTFFAVGYMLLLPLFAYFIRDWRMLLLALTVPGLCVPLWVFIPESPRWLISQRRFREAEDIIQKAAMNNIAPPAV
OCT2    -IFYQVAYTVGLLVLAGVAYALPHWRWLQFTVSLPNFFFLYYWCIPESPRWLISQNKNAEAMRIIKHIAKNGKSLPAS

OCTN1  IFDSVEELNPLKQKAFILDLFRTRNIAIMTMSLLWMLTSVGYFALS LDAPNLHGDAYLNCFLSALIEIPAYITAWLL
OCT2    LQRLRLEETGKKNLPSFLDLV RTPQIRKHTMILMYNWF TSSVLYQGLIMHGLAGDNIYLDFFYSALVEFPAAFMII LT

OCTN1  LRTLPRRYIIAAVLFWGGGVLLFIQLVPVDYFSLIGLVMLGKFGITSAFSMLYVFTAELYPTLVRNMAVGVTSTASRVG
OCT2    IDRIGRRYPWAASNMVAGAACLASVFIPGDLQWLKIIISCLGRMGITMAYEIVCLVNAELYPTFIRNLGVHICSSMCDIG

OCTN1  SIIAPYFVY-LGAYNRMLPYIVMGSLTVLIGILTFFPESLGMTLPETLEQMOKVKWFRSGKKTRDSMETEENPKVLITA
OCT2    GIITPFLVYRLTNIWLELPLMVFGVLGLVAGGLVLLLPETKGKALPETIEEAENMQRPKNKEKMIYLVQVKLDIPLN--

OCTN1  F
OCT2    -

```

20 **Supplementary Figure 2. CRAC and CARC cholesterol binding motif conservation.** The human
 21 OCTN1 and OCT2 protein sequences were aligned by ClustalX software. CRAC and CARC motif,
 22 conserved across the two proteins, are indicated as shadowed blue and orange boxes, respectively.